Aflibercept in patients with exudative AMD refractory to ranibizumab
Research type
Research Study
Full title
Efficacy of intravitreal aflibercept in patients with exudative AMD refractory to intravitreal ranibizumab
IRAS ID
161640
Contact name
Nachiketa Acharya
Contact email
Sponsor organisation
Sheffield Teaching Hospital
Duration of Study in the UK
0 years, 2 months, 27 days
Research summary
Age-related macular degeneration (AMD) is a common cause of blindness. It can be divided into wet and dry types. In the wet type, the mainstay of therapy is injections of anti-vascular endothelial growth factor (VEGF) drugs such as ranibizumab (Lucentis) and off-license bevacizumab (Avastin). In 2012, Heier et al. demonstrated that a new anti-VEGF drug, aflibercept (Eylea), produced similar efficacy and safety outcomes as monthly ranibizumab. Given the different mechanism of action, aflibercept offers an alternative treatment to patients who do not respond to ranibizumab. We aim to evaluate the response to aflibercept in patients with wet AMD who do not respond to ranibizumab in Sheffield. The study will take place at the Royal Hallamshire Hospital ophthalmology department in Sheffield, UK. We will review electronic patient medical records at initial presentation, at the time of switching to aflibercept, 2 months after switching and 4 months after switching.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
15/SC/0064
Date of REC Opinion
26 Jan 2015
REC opinion
Favourable Opinion